Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ryan Kuta

Pain Medicine Naperville, IL Doctor of Osteopathy

NPI 1851882278 CMS profile 4475703

2940 Rollingridge Rd Ste 201, Ste 466, Naperville, IL 60564

Open in the dashboard

General payments

$114,055

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryan Kuta of Naperville, IL is reported in the CMS Open Payments database as having received $114,055 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,588 69
2024 General $2,273 55
2023 General $9,039 109
2022 General $98,848 71
2020 General $21 1
2019 General $288 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryan Kuta
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Ryan Kuta were reported at $3,588. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Ryan Kuta Pain Medicine median Middle half National median
2019 $288 $498 $126–$1,682 $163
2020 $21 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $98,848 $455 $137–$1,484 $149
2023 $9,039 $484 $128–$1,495 $160
2024 $2,273 $498 $131–$1,540 $164
2025 $3,588 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $59,652 147 payments
  2. Boston Scientific Corporation $27,556 32 payments
  3. Medtronic, Inc. $20,457 11 payments
  4. Nevro Corp. $1,786 27 payments
  5. Saluda Medical Americas, Inc. $1,397 14 payments
  6. Nalu Medical, Inc. $646 6 payments
  7. MML US, Inc. $399 6 payments
  8. AbbVie, Inc. $381 11 payments
  9. BIOTRONIK NRO, Inc. $320 20 payments
  10. Globus Medical, Inc. $215 5 payments
  11. Other $1,245 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $95,053 4 payments
  2. Food and Beverage $13,025 281 payments
  3. Travel and Lodging $5,978 25 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 Pain Management $25,000 1 payment
  2. SYNCHROMEDII $20,262 5 payments
  3. PROCLAIM Neuromodulation $3,088 26 payments
  4. PROCLAIM Neuromodulation $2,477 59 payments
  5. PROCLAIM Structural Heart $2,285 17 payments
  6. Senza $1,174 19 payments
  7. Evoke SCS $1,030 6 payments
  8. Superion Indirect Decompression System $795 5 payments
  9. WaveWriter Alpha Prime 16 WaveWriter Alpha_NMD $758 7 payments
  10. General - Therapies $667 4 payments
  11. Other $6,714 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

857

Median for Pain Management: 951

Drug cost

$28,345

Median for Pain Management: $26,034

Branded share of claims

25.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 20 $19,324
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 199 $3,603
Oxycodone Hcl Generic 58 $966
Gabapentin Generic 106 $850
Tizanidine Hcl Generic 86 $818
Pregabalin Generic 50 $647
Cyclobenzaprine Hcl Generic 57 $518
Tramadol Hcl Generic 84 $416
Methylprednisolone Generic 56 $343
Celecoxib Generic 16 $322

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$182,980

Of which drugs: $1,449

Medicare patients

343

Average age 75

Services billed

6,584

197 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 32%
Chronic kidney disease 31%
Diabetes 29%
Depression 29%
Osteoporosis 23%
Atrial fibrillation 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 64 4,754 $485
Injection, methylprednisolone acetate, 40 mg J1030 Office 39 83 $397
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 18 81 $56

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record